David, you love to ask me that question. I could stay here for the next hour and talk about it, but I promise I won't. And we've been that contraction in the GDP from one of my colleagues to your last minute because it wasn't in my script, but I didn't want to seem like we were blond,-- we were blind to what was going on. Hey, one of the other reasons we talked about another benefit of doing this transaction and having a bigger balance sheet is that, again, from a concentration perspective it gives sponsor and specialty more running room under -- under a prudent portfolio approach to management -- to the way we manage it. So I will tell you that as of quarter-end, our regulatory defined definition of leverage loans was roughly 6% of the entire loan portfolio of the organization with like-credit performance to the rest of the portfolio as we've said before, that's held historically through both the great financial crisis, through the pandemic in that while there may be volatility in risk rating at times, it really -- it performed at or better than the rest of the portfolio and it goes to some of the things you're talking about. We feel like we're not involved in -- not that much involved in market level large syndicated deals. We have a lot of really good long-term relationship with private equity sponsors. We tend to play in areas that have repeatable, protectable, predictable cash flows. like our technology group, like our data center, and infrastructure group like our healthcare and healthcare services group. So they tend to be companies that during normal cycles actually have predictable cash flow, and obviously, during the pandemic, those did well. We don't do a lot of covenant light transactions. And you are right to say that one of the benefits are in these deals is there is a lot of cash equity underneath your senior debt, so it takes a real paradigm shift in any company's performance to have the private equity firm say, hey, we're added here or we want to give you the keys. And so, we tend to work with these private equity firms for literally more than 20 years in some cases, and have a really good relationship where the senior debt and the equity work gets a great outcome. So it is enterprise reliant. It doesn't have hard collateral underneath it, and I think that's why sometimes the market always asks the question, but I think we had a long and durable time to validate our strategies and underwriting in that area. And again, it's 6% of a $44 billion loan portfolio, so to also right-sized, I believe, where we are.